| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2025―May―30 |
RAAS Overactivation and Mitochondrial Damage Signaling as Key Players in Lethal COVID-19 |
Sabrina Fulkerson, Grace Hohman, Tyler Stark, Selman Aydogdu, Mohamed Eldeeb |
| 2 |
[GO] |
2023―Jul―30 |
Central Effects of Ivermectin in Alleviation of Covid-19-induced Dysautonomia |
|
| 3 |
[GO] |
2023―Jul―30 |
Molecular Modeling Targeting Transmembrane Serine Protease 2 (TIMPRSS2) as an Alternative Drug Target Against Coronaviruses |
|
| 4 |
[GO] |
2023―Mar―06 |
High-Throughput Screening for the Potential Inhibitors of SARS-CoV-2 with Essential Dynamic Behavior |
Zhiwei Yang, Xinhui Cai, Qiushi Ye, Yizhen Zhao, Xuhua Li, Shengli Zhang, Lei Zhang |
| 5 |
[GO] |
2022―Dec―06 |
Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology |
Cristina Vieira |
| 6 |
[GO] |
2022―Dec―06 |
Targeting Host Cell Proteases to Prevent SARS-CoV-2 Invasion |
Upinder Kaur |
| 7 |
[GO] |
2022―Nov―17 |
Coagulopathy and COVID-19 |
Victoria A. Ploplis |
| 8 |
[GO] |
2022―Oct―26 |
COVID-19 induces Cytokine Storm and Dysfunctional Hemostasis |
Victoria A. Ploplis, Jermilia Charles |
| 9 |
[GO] |
2022―Oct―18 |
ACE2 as a Key Target for Treatment of COVID-19 Related Cardiovascular Diseases: Current Progress and Prospect |
Shuainan Li |
| 10 |
[GO] |
2022―Oct―18 |
Role of Poly(ADP-ribose) Polymerase (PARP1) in Viral Infection and its Implication in SARS-CoV-2 Pathogenesis |
Jyotika Rajawat |
| 11 |
[GO] |
2022―Oct―14 |
Cell Entry and Unusual Replication of SARS-CoV2 |
Francis J. Castellino, Nathan McCann |
| 12 |
[GO] |
2022―Oct―12 |
Current Drug Targets (CDT) special issue on Covid-19 and Coagulopathy Fibrinolysis in COVID-19: impact on clot lysis and modulation of inflammation |
Lirlândia P. Sousa, Michelle A. Sugimoto, Luiza O. Perucci, Luciana P. Tavares, Mauro M. Teixeira |
| 13 |
[GO] |
2022―Oct―06 |
COVID-19 and Thrombosis: Clinical Aspects |
Tetsumei Urano, Atsushi Yasumoto, Kenji Yokoyama, Hisanori Horiuchi, Eriko Morishita, Yuko Suzuki |
| 14 |
[GO] |
2022―Sep―27 |
Tissue factor and COVID-19: an update |
Nigel Mackman, Ana Teresa Azevedo Sachettor |
| 15 |
[GO] |
2022―Sep―23 |
Gastrointestinal system, COVID-19 and potential mechanisms associated with coagulopathy |
Silvio Danese, Federica Furfaro, Roberto Gabbiadini, Ferdinando D’Amico, Alessandra Zilli, Arianna Dal Buono, Mariangela Allocca, Gionata Fiorino |
| 16 |
[GO] |
2022―Sep―19 |
Neurological Complications of SARS-CoV-2 Infection and COVID-19 Vaccines: From Molecular Mechanisms to Clinical Manifestations |
Manuel Yepes |
| 17 |
[GO] |
2022―Aug―27 |
Fibrinogen, Fibrin, and Fibrin Degradation Products in COVID-19 |
Kadri Kangro, Alisa S. Wolberg, Matthew J. Flick |
| 18 |
[GO] |
2022―Aug―11 |
Central effects of Ivermectin in alleviation of Covid-19-induced dysautonomia |
Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Athanasios Alexiou, Gaber El-Saber Batiha |
| 19 |
[GO] |
2022―Aug―05 |
Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology |
Cristina Vieira |
| 20 |
[GO] |
2022―Aug―05 |
Targeting Host Cell Proteases to Prevent SARS-CoV-2 Invasion |
Upinder Kaur |
| 21 |
[GO] |
2022―Jul―15 |
Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology |
Cristina Simões e Silva |
| 22 |
[GO] |
2022―Jul―15 |
Targeting Host Cell Proteases to Prevent SARS-CoV-2 Invasion |
Sankha Shubhra Chakrabarti |
| 23 |
[GO] |
2022―Jun―24 |
The Role of Host-Cellular Responses in COVID-19 Endothelial Dysfunction |
Thomas E. Moran, Daniel E. Hammers, Shaun W. Lee |
| 24 |
[GO] |
2022―Apr―20 |
Current drug targets for gut microbiota biocorrection during the SARS-CoV-2 pandemic: a systematic review. |
Maria V. Sankova, Vladimir N. Nikolenko, Marine V. Oganesyan, Anastasia A. Bakhmet, Lilia V. Gavryushova, Sergey V. Sankov, Mikhail Y. Sinelnikov |
| 25 |
[GO] |
2022―Mar―17 |
Free ISG15 and protein ISGylation emerging in SARS-CoV-2 infection |
Angeles C. Tecalco Cruz |
| 26 |
[GO] |
2021―Nov―04 |
Potential implications of angiotensin-converting enzyme 2 blockades on neuroinflammation in SARS-CoV-2 infection |
Deepraj Paul, Suresh Kumar Mohankumar, Rhian S Thomas, Chai Boon Kheng, Duraiswamy Basavan |
| 27 |
[GO] |
2021―Oct―23 |
A Mechanistic Review on Plant-derived Natural Inhibitors of Human Coronaviruses with Emphasis on SARS-COV-1 and SARS-COV-2 |
Sai Krishna Guguloth, A R Lakshmi, Radhika Rajendran, Kaushik Rajaram, Thirunavukkarasu Chinnasamy, Jian-Dong Huang, Hongjie Zhang, Sanjib Senapati, Siva Sundara Kumar Durairajan |
| 28 |
[GO] |
2021―Sep―07 |
Exploring the SARS-CoV-2 main protease (Mpro) and RdRp targets by updating current structure-based drug design utilizing co-crystals to combat COVID-19 |
Heena Tarannum, Sisir Nandi |
| 29 |
[GO] |
2021―Aug―09 |
Molecular Modeling Targeting Transmembrane Serine Protease 2 (TMPRSS2) as an Alternative Drug Target Against Coronaviruses |
Igor José dos Santos Nascimento, Edeildo Ferreira da Silva-Júnior, Thiago Mendonça de Aquino |
| 30 |
[GO] |
2021―Mar―22 |
ACE2 as a key target for treatment of COVID-19 related cardiovascular diseases: current progress and prospect |
Shuainan Li, Benzhi Cai, Wenya Ma, Fan Yang, Yan Xu, Binbin Xu |
| 31 |
[GO] |
2021―Mar―10 |
Exploring Spike Protein as Potential Target of Novel Coronavirus and to Inhibit the Viability utilizing Natural Agents |
Sisir Nandi, Harekrishna Roy, Asha Gummadi, Anil Saxena |
| 32 |
[GO] |
2021―Feb―16 |
Small-molecule antiviral agents in ongoing clinical trials for COVID-19 |
Çağla Begüm Apaydın, Gözde Çınar, Gökçe Cihan-Üstündağ |
| 33 |
[GO] |
2021―Jan―26 |
Role of Poly(ADP-ribose) polymerase (PARP1) in viral infection and its implication in SARS-CoV-2 pathogenesis |
Jyotika Rajawat, Abhishek Chandra |
| 34 |
[GO] |
2020―Dec―29 |
Remdesivir and Hydroxychloroquine: A Compassionate Use in Covid-19 |
Amritpal Kaur, Gaurav Chaudhary, Pargat Singh, Sandeep Arora, Rajwinder Kaur |
| 35 |
[GO] |
2020―Dec―29 |
A Review on Screening Models for Potential Therapeutic Candidates and Targets Against SARS-CoV-2 |
Mohana Das, Manish Kumar, Abhishek Jha, Kanchan Bharti, Shomedeep Mondal, Brahmeshwar Mishra |
| 36 |
[GO] |
2020―Dec―03 |
Remdesivir (GS-5734) in COVID-19 Therapy: The Fourth Chance |
Dinesh Singh Moirangthem, Laishram Surbala |
| 37 |
[GO] |
2020―Nov―27 |
Can Host Cell Proteins Like ACE2, ADAM17, TMPRSS2, Androgen Receptor be the Efficient Targets in SARS-CoV-2 Infection? |
Vivek Gupta, Madhan Kumar Murthy, Shripad Patil |
| 38 |
[GO] |
2020―Oct―21 |
Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology |
Cristina Vieira, Lucas Nery, Ludimila Martins, Luiz Jabour, Raphael Dias, Ana Cristina Simões e Silva |
| 39 |
[GO] |
2020―Oct―14 |
COVID-19 and Renal Diseases: An Update |
Letícia Bitencourt Cota, Ana Luisa Pedrosa, Stephanie Bruna Camilo Soares de Brito, Ana Cláudia Fontoura Fróes, Sarah Tayná de Carvalho, Giulio Gori Fonseca, Guilherme Costa Ferreira, Pollyanna Faria Fradico, Ana Cristina Simões e Silva |
| 40 |
[GO] |
2020―Oct―07 |
Therapeutic Options for Treatment of COVID-19: A Review from Repur-posed Drugs to New Drug Targets |
Bushra Akhtar, Faqir Muhammad, Ali Sharif, Abdul Hannan |
| 41 |
[GO] |
2020―Sep―25 |
Targeting host cell proteases to prevent SARS-CoV-2 invasion |
Upinder Kaur, Sankha Shubhra Chakrabarti, Bisweswar Ojha, Bhairav Kumar Pathak, Amit Singh, Luciano Saso, Sasanka Chakrabarti |
| 42 |
[GO] |
2020―Jun―17 |
Facts and myths: Efficacies of repurposing chloroquine and hydroxychloroquine for the treatment of COVID-19 |
Md. Abdul Alim Al-Bari |
